Form 4: Omeros Corp Director Arnold C Hanish Acquires 15,000 Shares Through Stock Option Grant

Director Arnold C Hanish acquired 15,000 shares of Omeros Corp through a stock option grant on June 6, 2024, as part of the company's non-employee director compensation policy.

Summary

• On June 6, 2024, Arnold C Hanish, a director of Omeros Corporation, was granted a stock option to purchase 15,000 shares of common stock.
• The grant is part of Omeros Corporation's non-employee director compensation policy.
• The option was awarded in conjunction with the annual meeting of shareholders held on June 6, 2024.
• The exercise price of the stock option is $3.91.
• The option will fully vest and become exercisable on the day before the date of the 2025 annual meeting of the shareholders of Omeros Corporation, contingent upon the reporting person continuing to serve as a director through that date.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The stock option grant is a routine part of director compensation and aligns interests with shareholders. There are no immediate negative implications.

Positives

• The stock option grant aligns the director's interests with those of the shareholders.
• The vesting schedule incentivizes continued service as a director.

Future Outlook

The director's continued service is incentivized through the vesting schedule of the stock option.

Industry Context

Stock option grants are a common form of compensation for non-employee directors, aligning their interests with those of shareholders and incentivizing their continued service.

Comparison to Industry Standards

• Director compensation packages, including stock options, vary widely across the biotechnology industry depending on company size, stage of development, and performance.
• Comparing Omeros' director compensation to companies like Amgen, Biogen, or Gilead Sciences would provide context, but these companies are significantly larger.
• A more relevant comparison would be to peer companies of similar market capitalization and development stage, such as Seattle Genetics (now Seagen before being acquired by Pfizer) or BioMarin Pharmaceutical, to assess the competitiveness of the compensation package.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it aligns the director's interests with the company's long-term success.
• The grant has no immediate impact on employees, customers, suppliers, or creditors.

Key Dates